Creo Medical GroupCMEOF 53 Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus rates CMEOF with a GF Score™ of 53/100 and a GF Value™ of $0.25. The stock has 6 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Creo Medical Group ranks worse than 214132.55% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Creo Medical Group's
Operating Income
for the
six
months ended in Dec. 2025 was $-12.72 Mil. Creo Medical Group's Interest Expense for the
six
months ended in Dec. 2025 was $-0.27 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Creo Medical Group's Interest Coverage or its related term are showing as below:
CMEOF's Interest Coverage is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 15.72 * Ranked among companies with meaningful Interest Coverage only.
Creo Medical Group (OTCPK:CMEOF) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Creo Medical Group Interest Coverage Related Terms
Creo Medical Group Interest Coverage Historical Data
* Premium members only.
The historical data trend for Creo Medical Group's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CMEOF vs ABT, SYK, MDT: Interest Coverage Comparison
For the Medical Devices subindustry, Creo Medical Group's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creo Medical Group Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Creo Medical Group's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Creo Medical Group did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Creo Medical Group (CMEOF) has a Interest Coverage of 0 (At Loss) as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Creo Medical Group and its competitors. According to the industry distribution chart, Creo Medical Group ranks #999999 out of 467 companies in the Medical Devices & Instruments industry.
Is Creo Medical Group's Interest Coverage too high?
Creo Medical Group's current Interest Coverage is 0 (At Loss). Based on the distribution chart, Creo Medical Group ranks #999999 out of 467 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Creo Medical Group has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's Interest Coverage compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Creo Medical Group ranks #999999 out of 467 companies for Interest Coverage. This places Creo Medical Group in the lower half of its industry. The industry median Interest Coverage is 15.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 15.72, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Creo Medical Group and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 15.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creo Medical Group's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (CMEOF) has a current Interest Coverage of 0 (At Loss). The stock's GF Value™ is $0.25, compared to a current price of $0.20 — trading 20% below its estimated fair value. The current Interest Coverage is 0 (At Loss). Creo Medical Group's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current Interest Coverage is 0 (At Loss) as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creo Medical Group (CMEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued.
The current stock price of $0.20 is trading 20% below its estimated GF Value™ of $0.25.
Key valuation signals for CMEOF:
Interest Coverage: 0 (At Loss)
GF Value™: $0.25 vs. price of $0.20 (20% below fair value)
No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
53GF Score
Get the complete analysis for CMEOF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMEOF has been successfully added to your 
